Targeted Dosing as a Precision Health Approach to Pharmacotherapy in Children with Inflammatory Bowel Disease

Anava A Wren; K T Park

doi:10.1001/amajethics.2018.841

Targeted Dosing as a Precision Health Approach to Pharmacotherapy in Children with Inflammatory Bowel Disease

AMA J Ethics. 2018 Sep 1;20(9):E841-848. doi: 10.1001/amajethics.2018.841.

Authors

Anava A Wren¹, K T Park²

Affiliations

¹ An instructor in the Department of Pediatrics, Division of Gastroenterology, at Stanford University School of Medicine in Palo Alto, California, and a clinical psychologist at Stanford Children's Inflammatory Bowel Disease (IBD) Center, where she provides support to pediatric patients and families from diagnosis of IBD through their transition to adult care.
² An associate professor in the Department of Pediatrics, Division of Gastroenterology, at Stanford University School of Medicine in Stanford, California, and the codirector of Stanford Children's Inflammatory Bowel Disease (IBD) Center.

PMID: 30242815
DOI: 10.1001/amajethics.2018.841

Abstract

As clinicians have begun to provide targeted pharmacotherapy for children with inflammatory bowel disease (IBD), several ethical challenges have arisen. In this paper, we review 3 challenges related to applying a precision health approach to pediatric IBD populations: selection of a disease monitoring method, pharmacotherapy optimization, and economic considerations in clinical decision making.

MeSH terms

Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / economics
Child
Child Health / ethics*
Health Care Costs
Humans
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / economics
Pediatrics / economics
Pediatrics / ethics*
Pediatrics / methods
Practice Patterns, Physicians' / economics
Practice Patterns, Physicians' / ethics*
Precision Medicine / economics
Precision Medicine / ethics*
Precision Medicine / methods

Substances

Anti-Inflammatory Agents